In amyotrophic lateral sclerosis and frontotemporal dementia, loss of the RNA-binding protein TDP-43 from the nucleus creates a surge of mis-spliced mRNAs in neurons. So far, only one of these errant ...

AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026 Initial data indicates significantly higher tracer uptake in patients with ...

BOSTON--(BUSINESS WIRE)--SOLA Biosciences, a pioneer in innovative chaperone technology, will present its encouraging preclinical proof-of-concept data for SOL-257, a targeted gene therapy for ...

The pathological accumulation of TDP-43 that underlies many cases of FTD, ALS, and LATE-NC has been notoriously difficult to recapitulate in mice or cultured human cells. In a paper published February ...

Brain levels of TAR DNA binding protein 43 (TDP-43), a key factor in the neurodegeneration that occurs with Alzheimer's disease, begin declining nearly two decades prior to the end of life and show an ...

BOSTON--(BUSINESS WIRE)--As a pioneer in innovative chaperone technology, SOLA Biosciences Inc. will present its compelling preclinical proof-of-concept data for SOL-257, a targeted gene therapy for ...

Niigata, Japan - Amyotrophic lateral sclerosis (ALS) is an intractable neurological disease. Aging is a risk factor for the accumulation of TDP-43 (transduction responsive region DNA-binding protein ...

TDP-43 CYTOPE® preclinical data demonstrates the potential of Prothena’s CYTOPE technology as a novel modality for delivering large molecules into cells, enabling precise targeting of intracellular ...

The TDP-43 RNA-binding protein is found in abnormal cytoplasmic inclusions in affected motor neurons in almost all ALS cases, and mutations in the TDP-43 gene (TARDBP) cause a rare form of familial ...

First-in-class condensate-modulating small molecule Development Candidate targeting pathogenic TDP-43 condensates. Restores global TDP-43 splicing function in disease-relevant systems. Demonstrates in ...